235 related articles for article (PubMed ID: 14576847)
1. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.
Hazlehurst LA; Landowski TH; Dalton WS
Oncogene; 2003 Oct; 22(47):7396-402. PubMed ID: 14576847
[TBL] [Abstract][Full Text] [Related]
2. [Research advance on role of tumor microenvironment in mediating acquired drug resistance].
Ma XL; Xing H; Ma D
Ai Zheng; 2007 Aug; 26(8):923-6. PubMed ID: 17697561
[TBL] [Abstract][Full Text] [Related]
3. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
Meads MB; Hazlehurst LA; Dalton WS
Clin Cancer Res; 2008 May; 14(9):2519-26. PubMed ID: 18451212
[TBL] [Abstract][Full Text] [Related]
4. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
5. Integrin-mediated cell-matrix interactions for prosurvival and antiapoptotic signaling after genotoxic injury.
Cordes N
Cancer Lett; 2006 Oct; 242(1):11-9. PubMed ID: 16448744
[TBL] [Abstract][Full Text] [Related]
6. Overview of tumor cell chemoresistance mechanisms.
Gatti L; Zunino F
Methods Mol Med; 2005; 111():127-48. PubMed ID: 15911977
[TBL] [Abstract][Full Text] [Related]
7. Avoidance of apoptosis as a mechanism of drug resistance.
Dive C
J Intern Med Suppl; 1997; 740():139-45. PubMed ID: 9350196
[TBL] [Abstract][Full Text] [Related]
8. Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review).
Fedier A; Fink D
Int J Oncol; 2004 Apr; 24(4):1039-47. PubMed ID: 15010846
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance mechanisms in cancer cells: a proteomics perspective.
Verrills NM; Kavallaris M
Curr Opin Mol Ther; 2003 Jun; 5(3):258-65. PubMed ID: 12870435
[TBL] [Abstract][Full Text] [Related]
10. Bypassing cancer drug resistance by activating multiple death pathways--a proposal from the study of circumventing cancer drug resistance by induction of necroptosis.
Hu X; Xuan Y
Cancer Lett; 2008 Feb; 259(2):127-37. PubMed ID: 18082322
[TBL] [Abstract][Full Text] [Related]
11. The tumor microenvironment as a determinant of drug response and resistance.
Dalton WS
Drug Resist Updat; 1999 Oct; 2(5):285-288. PubMed ID: 11504502
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of drug resistance.
Longley DB; Johnston PG
J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.
Hartmann TN; Burger JA; Glodek A; Fujii N; Burger M
Oncogene; 2005 Jun; 24(27):4462-71. PubMed ID: 15806155
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment and drug resistance in hematologic malignancies.
Li ZW; Dalton WS
Blood Rev; 2006 Nov; 20(6):333-42. PubMed ID: 16920238
[TBL] [Abstract][Full Text] [Related]
15. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors.
Tomida A; Tsuruo T
Anticancer Drug Des; 1999 Apr; 14(2):169-77. PubMed ID: 10405643
[TBL] [Abstract][Full Text] [Related]
17. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance.
Shain KH; Landowski TH; Dalton WS
Curr Opin Oncol; 2000 Nov; 12(6):557-63. PubMed ID: 11085455
[TBL] [Abstract][Full Text] [Related]
18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
19. DNA-damage sensitizers: potential new therapeutical tools to improve chemotherapy.
Michod D; Widmann C
Crit Rev Oncol Hematol; 2007 Aug; 63(2):160-71. PubMed ID: 17544289
[TBL] [Abstract][Full Text] [Related]
20. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
